biostudies-literatureUnknown15Teragawa H<h4>Purpose</h4>The effects of two types of dipeptidyl peptidase-4 (DPP-4) inhibitors on renal function remain unclear. Thus, we investigated the effect of anagliptin (ANA) and sitagliptin (SITA) on renal function in patients with type 2 diabetes who participated in the randomized evaluation of ANA versus SITA on low-density lipoprotein-cholesterol (LDL-C) in diabetes (REASON) trial.<h4>Patients and methods</h4>We measured the estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio (UACR) before and after the REASON trial. ANA 200 mg/day was administered to 177 patients for 52 weeks, while SITA 50 mg/day was given to 176 patients. We investigated the relationship between differences in renal function and differences in hemoglobin A1c (HbA1c) levels, LDL-C levels, aDiabetes, metabolic syndrome and obesity : targets and therapy685-694https://www.ebi.ac.uk/biostudies/studies/S-EPMC8901417biostudies-literatureEffect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial.PMC8901417Teragawa HMorimoto TShimabukuro MSakuma MArasaki ONomiyama TFujii YNode KUeda SUeda TfalseEffect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial.<h4>Purpose</h4>The effects of two types of dipeptidyl peptidase-4 (DPP-4) inhibitors on renal function remain unclear. Thus, we investigated the effect of anagliptin (ANA) and sitagliptin (SITA) on renal function in patients with type 2 diabetes who participated in the randomized evaluation of ANA versus SITA on low-density lipoprotein-cholesterol (LDL-C) in diabetes (REASON) trial.<h4>Patients and methods</h4>We measured the estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio (UACR) before and after the REASON trial. ANA 200 mg/day was administered to 177 patients for 52 weeks, while SITA 50 mg/day was given to 176 patients. We investigated the relationship between differences in renal function and differences in hemoglobin A1c (HbA1c) levels, LDL-C levels, a2022-01-01T00:00:00Z20222025-04-04T07:50:52.382Z2025-04-04T07:50:52.382ZS-EPMC89014173526486310.2147/DMSO.S350518